Antifungal News and Research

RSS

Two existing drugs may reverse damage caused by multiple sclerosis

A pair of topical medicines already alleviating skin conditions each may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple sclerosis.

21 Apr 2015

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis.

20 Apr 2015

LifeThreads introduces new line of antimicrobial linens

A new line of antimicrobial linens that inhibit the growth of bacteria on their surface are being introduced by LifeThreads LLC here at the Clean Show 2015, booth 4116, at the Georgia World Congress Center.

16 Apr 2015

Itraconazole drug shows potential in cancer treatment

A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience.

16 Apr 2015

New study describes economic consequences of using T2Candida Panel for detection of candidemia

A new study describes a model that estimates the economic consequences of using the T2Candida Panel (a novel diagnostic product that provides Candida detection) as an adjunct to the current blood culture-based diagnostic strategy in a high-risk hospital patient cohort.

9 Apr 2015

New approach could help identify novel drug targets to combat lethal fungal infections

By modifying the CRISPR-Cas genome editing system, Whitehead Institute researchers are now able to manipulate Candida albicans' genome systematically--an approach that could help identify novel targets for therapies against this serious pathogen for which there are a limited number of anti-fungal agents.

6 Apr 2015

TSRI scientists uncover unique mechanism of natural product with antimicrobial, anti-cancer effects

Scientists from the Florida campus of The Scripps Research Institute have uncovered the unique mechanism of a powerful natural product with wide-ranging antifungal, antibacterial, anti-malaria and anti-cancer effects.

1 Apr 2015

New study sheds light on natural small molecule with antimicrobial effects

31 Mar 2015

Authors examine potential reasons for the persistence of FC, other autism fads

The communication struggles of children with autism spectrum disorder can drive parents and educators to try anything to understand their thoughts, needs and wants. Unfortunately, specialists in psychology and communication disorders do not always communicate the latest science so well.

28 Feb 2015

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western Reserve University dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice.

23 Feb 2015

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients’ health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

Bayer offers wide range of material solutions for OEMs' medical application needs

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients' health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments.

19 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer.

8 Dec 2014

CorMedix seeks QIDP designation from FDA for Neutrolin Catheter Lock Solution

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration for designation of its lead product candidate, Neutrolin Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act.

4 Dec 2014

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas announced today that the U.S. Food and Drug Administration has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis.

3 Nov 2014

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa.

8 Oct 2014

Fogarty receives three grants for research focused on biodiversity conservation

In addition to diseases for which there are ineffective or no cures, key pathogens are becoming increasingly drug-resistant.

10 Sep 2014

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.

8 Sep 2014